Yarrow Bioscience, Inc. Common Stock
YARW
58 hedge funds and large institutions have $20.1M invested in Yarrow Bioscience, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 18 reducing their positions, and 12 closing their positions.
338% more call options, than puts
Call options by funds: $140K | Put options by funds: $32K
0.01% less ownership
Funds ownership: 0.04% → 0.03% (-0.01%)
8% less funds holding
Funds holding: 63 → 58 (-5)
22% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 18
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
69% less capital invested
Capital invested by funds: $64M → $20.1M (-$43.9M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$2.01M |
| 2 |
VF
Virtu Financial
New York
|
+$233K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$200K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$120K |
| 5 |
Two Sigma Investments
New York
|
+$73.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$7.42M |
| 2 |
DAM
Deltec Asset Management
New York
|
-$768K |
| 3 |
E
Ergoteles
New York
|
-$557K |
| 4 |
Millennium Management
New York
|
-$533K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$426K |
YARW Hedge Fund Activity: Q3 2021 in Review
58 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q3 2021, worth a combined $20.1M — down 69% from $64M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of YARW and 7 opened new positions — a net loss of 5 holders — while 18 trimmed existing stakes and 14 added.
The largest buyer was Renaissance Technologies, adding an estimated $2.01M. The largest seller was Perceptive Advisors, cutting an estimated $7.42M.
- 58 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q3 2021, down from 63 in Q2 2021.
- Funds reported $20.1M of Yarrow Bioscience, Inc. Common Stock stock for Q3 2021, down 69% quarter-over-quarter.
- 7 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q3 2021 and 12 closed out, a net change of -5 holders.
- The largest Yarrow Bioscience, Inc. Common Stock buyer in Q3 2021 was Renaissance Technologies, an estimated $2.01M added.
- The largest Yarrow Bioscience, Inc. Common Stock seller in Q3 2021 was Perceptive Advisors, an estimated $7.42M sold.
Based on aggregated 13F filings for Q3 2021.